Genmab’s Strong Performance and Future Uncertainties: A Balanced Hold Rating by Yaron Werber

Analyst Yaron Werber from TD Cowen maintained a Hold rating on Genmab and increased the price target to $24.00 from $20.00.

Yaron Werber has given his Hold rating due to a combination of factors influencing Genmab’s current and future prospects. The company’s recent quarterly performance was strong, with revenues exceeding expectations, largely driven by robust royalties from Darzalex and Kesimpta, as well as impressive sales of Epkinly. However, despite this solid commercial performance, there are concerns about Genmab’s ability to navigate the impending Darzalex patent expiration by 2030, which adds a layer of uncertainty to its long-term outlook.
While Epkinly shows promise with its expanding sales across multiple regions and positive clinical data, the upcoming Phase 3 trial results, particularly for 1L/2L DLBCL, will be crucial in determining its potential to achieve significant revenue targets. Additionally, although Rina-S and acasunlimab are progressing in their respective trials, the competitive landscape and previous mixed results in certain areas temper the overall optimism. Consequently, Werber’s Hold rating reflects a balanced view, acknowledging both the positive developments and the challenges ahead for Genmab.